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FOXP3 INTERACTS WITH AND REGULATES HIF-1a-VEGF SIGNALING IN
HUMAN BLADDER CANCER
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Purpose: To investigate the prognostic role and molecular mechanism of
Foxp3 expression in human bladder cancer.
Materials and Methods: Using quantitative RT-PCR and western blotting
analysis, T24 parental and metastatic sublines were investigated for Foxp3,
glucose transporter ( GLUT), and VEGF expression. The interaction be-
tween Foxp3 and HIF-1a were explored using immunoprecipitation, and
confocal microscopic studies. Foxp3 expression was examined for the
prognostic values in bladder urothelial carcinoma using Foxp3 and CD8
immunostaining. Using data mining, the association between Foxp3, VEGF,
and GLUT member expression were explored.
Results: Foxp3 expression is associated with the metastatic potential
among three human bladder cancer T24 sublines, as well as higher
expression of glucose transporter (GLUT) members and vascular endo-
thelial growth factor (VEGF) expression and more aerobic glycolysis. Via
immunoprecipitation, and confocal microscopic studies, Foxp3 protein can
bind with and maintain HIF-1a expression post-translationally. Knocking-
down of Foxp3 expression blocks in vivo tumor growth in mice and pro-
longs mice's survival, which is associated with von Willebrand factor
expression. Forty-three of 145 (22.8 %) bladder tumors exhibit Foxp3
expression. Foxp3 expression is an independent predictor for disease
progression in superﬁcial bladder cancer patients (p¼0.032), associated
with less number of intratumoral CD8+ lymphocyte. The metaanalysis
from 2 published datasets showed Foxp3 expression is associated with
GLUT-4,-9, and VEGF-A, B-, D expression
Conclusion: Foxp3 expression in bladder tumor cells can bind with and
regulate HIF-1a signaling post-translationally, contributing to be an in-
dependent prognostic marker for progression in bladder cancer.
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Purpose: Renal cell carcinoma (RCC) accounts for about 3% of all cancer-
related mortalities worldwide and the risk factors for the development of
RCC have not yet been fully elucidated. Mounting proteomic evidence
suggests that inﬂammatory process plays a role in RCC etiology, and
interleukin-10 (IL-10) is an important immunosuppressive cytokine.
However, little is known about the contribution of IL-10 genotypes to RCC.
The study aimed at evaluating the contribution of IL-10 promoter A-1082G
(rs1800896), T-819C (rs3021097), A-592C (rs1800872) genetic poly-
morphisms to the risk of RCC in Taiwan.
Materials and Methods: Associations of the three IL-10 polymorphic ge-
notypeswith the risk of RCCwere examined among 92 RCC patients and580
age- and gender-matched cancer-free controls by polymerase chain reac-
tion-restriction fragment length polymorphism (PCR-RFLP) methodology.* These authors contribute equally to this workResults: The pilot results showed that the percentages of TT and TC for IL-
10 T-819C genotypes were signiﬁcantly higher in the RCC patient group
than those in the healthy control group. The CC genotype carriers were of
lower risk for RCC (odds ratio¼0.45, 95% conﬁdence interval¼0.23-0.72,
p¼0.0033). There is no difference in the distribution of A-1082G or A-592C
genotype between the RCC and control groups.
Conclusion: In summary, the CC genotype of IL-10 T-819C genotype may
have a protective effect on RCC risk in Taiwan. Further investigation with
larger sample size in addition to genotype-phenotype correlation and
intracellular mechanisms are our future work.
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Purpose: To follow up the oncologic outcomes of patients who underwent
nephroureterectomy with endoscopic bladder cuff excision (Pluck
method) under the diagnosis of upper tract urothelial carcinoma.
Materials and Methods: Between May 2004 to November 2015, 147 pa-
tients with upper urinary tract urothelial carcinoma received laparoscopic
radical nephroureterectomy with endoscopic bladder cuff excision at our
institution. The medical records were reviewed retrospectively for clinical
and pathological facts. Statistical analyses were made for factors theoret-
ically related to predicting oncological outcomes.
Results: The median follow-up time was 26 months. 27 patients (22.9%)
developed bladder recurrence as local recurrence found in 4 cases (3.4%).Me-
tastaseswere found in 17 patients (14.4%).Male genderwas statistical signiﬁ-
cantly related to bladder recurrence inmultivariate analysis (OR: 2.2; 95%C.I.:
1.02 e 4.78; p: 0.045). Tumor size was the only predictive factor for local
recurrence(mean:5.0cmversus3.2cm;OR:1.29;95%C.I.:1.07e3.43;p:0.029).
Tumor stagingwas related to subsequentmetastasis (OR: 2.08; 95%C.I.: 1.21e
3.56; p: 0.008) and overall survival (OR: 1.84; 95%C.I.: 1.06e 3.22; p: 0.031).
Conclusion: In patients with upper tract urothelial carcinoma received
laparoscopic nephroureterectomy with pluck method bladder cuff exci-
sion, the prognostic factor of bladder recurrence is male gender as larger
tumor indicating higher risk of locoregional recurrence. Advanced staging
carries higher possibility of subsequent metastasis and mortality.
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Purpose: Current guidelines suggest that patients with intermediate- or
high-risk prostate cancer (CaP) could be offered neoadjuvant hormone
therapy (NHT) before they receive deﬁnitive radiation therapy. However,
no powerful evidences showed NHT has prognostic beneﬁts to patients
receiving robotic-assisted laparoscopic radical prostatectomy (RaLRP) yet.
This study was to compare the results of RaLRP in patients who did and did
not receive NHT, especially focus on intermediate- and high-risk patients.
Materials and Methods: Patients received NHT prior to RaLRP by a single
surgeon were identiﬁed from the VGHTC Prostate Cancer Database. Con-
trol group was picked out via computerized 1:1 ratio matching with the
following criteria: (1) prostate speciﬁc antigen (PSA) level at diagnosis (2)
initial Gleason score (3) clinical stage (4) Age. NHT regimens include
combination of Luteinising hormone-releasing hormone (LHRH) agonist
with anti-androgens and individual use of either LHRH agonist or anti-
androgens. General characters of patients, peri-operative parameters,
functional and oncologic outcome were prospectively recorded.
